Tempus AI Inc

TEM

86.380USD

-2.400-2.70%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

6 / 507

Overall Ranking

107 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

73.409

Target Price

-7.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 123.50.

Overvalued

The company’s latest PE is 40.31, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 136.83M shares, decreasing 2.27% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 12.09M shares of this stock.

The company's current financial score is 7.31, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 255.74M, representing a year-over-year increase of 75.38%, while its net profit experienced a year-over-year increase of 26.89%.

Score

Industry at a Glance

Previous score

7.31

Change

0



Financials

7.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.38

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.84

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.07

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is 34.17, which is -114.84% below the recent high of -5.07 and 124.49% above the recent low of -8.37.

Score

Industry at a Glance

Previous score

5.17

Change

-0.14

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/507

No Data

The company’s current earnings forecast score is 7.54, which is lower than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Tempus AI Inc is 70.00, with a high of 85.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

7.73

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 87.88 and the support level at 55.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.77

Change

0.43

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 81.41%, representing a quarter-over-quarter increase of 0.21%. The largest institutional shareholder is Baillie Gifford, holding a total of 12.09M shares, representing 7.17% of shares outstanding, with 18.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Blue Media, LLC

25.83M

-2.87%

BK TL21 LLC

15.22M

--

Baillie Gifford & Co.

Star Investors

12.29M

-10.62%

Lefkofsky (Eric Paul)

4.54M

-0.37%

Red Sky LLC

9.50M

-17.83%

Gray Media, LLC

9.41M

-1.57%

The Vanguard Group, Inc.

Star Investors

6.00M

+6247.46%

ARK Investment Management LLC

Star Investors

7.50M

+35.90%

SoftBank Group Corp

5.41M

--

Nikko Asset Management Co., Ltd.

4.26M

+31.38%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.17, which is lower than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Tempus AI Inc

TEM

6.99 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Protagonist Therapeutics Inc

PTGX

7.04 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.